Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Breast Cancer Clinical Trial

Official title:

An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06123286
• Other study ID #: IIT2022-08-CHANG-TaCO3AIMSS
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: July 2024
• Est. completion date: July 2026

Study information

• Verified date: May 2024
• Source: Cedars-Sinai Medical Center
• Contact: Clinical Trial Navigator
• Phone: 3104232133
• Email: cancer.trial.info[@]cshs.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics the investigators often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia.

There is some evidence in mouse models that when given together, these supplements may have an even greater anti-inflammatory effect than when taken separately. Although to our knowledge, no human studies have tested this hypothesis. This study has been designed to test the hypothesis that Tart Cherry and fish oil when given in combination over a 12-week period could produce beneficial changes in arthritis symptoms when compared to a control group in an obese breast cancer population experience AIMSS and on an AI. Secondary outcomes to be assessed include pain, functional performance, quality of life and cognition.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Breast cancer diagnosis (Stage I-III) with any hormonal status.

• Females aged = 18 years.

• Currently receiving AI therapy.

• BMI = 27.

• Clinical diagnosis of AIMSS.

• Omega-3 Index <8%.

• Average joint pain score = 4 on the Brief Pain Inventory (BPI) within 7 days of enrollment.

• Written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study.

Exclusion Criteria:

• Current use of anticoagulant medications (Including but not limited to Warfarin, Lovenox, Eliquis, Xarelto).

• Allergy to cherries or fish/fish products.

• Lifetime history of rheumatoid arthritis and/or inflammatory joint diseases (Including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis).

• Uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and/or insulin).

• Lifetime history of stroke or transient ischemic attacks.

• New use or dose change of oral or topical analgesics in the previous 14 days. (Including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, SNRI's, SSRI's, gabapentinoids, tricyclic antidepressants, and muscle relaxants).

• Oral or intra-articular steroid use in the previous 30 days (Including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone).

• History of joint fracture or surgery of the symptomatic joint in the previous 6 months.

Related Conditions & MeSH terms

• Arthralgia
• Breast Cancer
• Joint Pain

Intervention

Dietary Supplement:
• Tart Cherry
1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
• Omega 3 FA (Fish Oil)
2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) [650 mg EPA and 450 mg DHA per capsule] daily for 12 weeks

Locations

Country	Name	City	State
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	CS Cancer at the Hunt Cancer Center	Torrance	California

Sponsors (2)

Lead Sponsor	Collaborator
Philip Chang	The Cherry Marketing Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective is to assess changes in arthritis symptoms between groups.	Changes in arthritis symptoms will be assessed via the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC Pain score ranges from 0% to 100% with higher scores indicating greater difficulty with activities of daily living.	6 Months
Secondary	To assess changes in nociplastic pain between groups.	Changes in nociplastic pain will be measured by composite score on Symptom Severity Scale. The Symptom Severity Scale ranges from 0-12 with higher scores equating to increased nociplastic pain.	6 Months
Secondary	To assess changes in nociplastic pain between groups.	Changes in nociplastic pain will be measured by composite score on Widespread Pain Index. The Widespread Pain Index score ranges from 0-19 with higher scores equating to increased nociplastic pain.	6 Months
Secondary	To assess changes in functional performance between groups.	Functional Performance will be measured by changes in the Patient-Reported Outcomes Measurement Information System (PROMIS) Cancer 3D Function Profile. The PROMIS Cancer 3D Function Profile has 3 subgroups including Physical Function, Fatigue and Social Participation. The Physical Function score ranges from 5-30 with higher scores equating to better function. The Fatigue score ranges from 3-15 with higher scores equating to less fatigue. The Social Participation score ranges from 3-15 with higher scores equating to worse social participation.	6 Months
Secondary	To assess changes in quality of life between groups.	Quality of Life will be measured by changes in the Patient-Reported Outcomes Measurement Information System (PROMIS) PROMIS-29+2. The PROMIS-29+2 has 8 subgroups including physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles, pain interference and cognitive function. All subgroups are scored from 4-20 except for cognitive function which is scored from 2-10.	6 Months
Secondary	To assess changes in cognition between groups.	Cognition will be measured by changes in the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function 8a Short Form. The PROMIS Cognitive Function Short Form 8a score ranges from 8 to 40 with higher scores indicating better cognitive function.	6 Months